Publication:
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

dc.contributor.authorSimmons, Cameron
dc.date.accessioned2018-09-14T11:15:09Z
dc.date.available2017-07-12T03:27:52Z
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2014-11-18en_US
dc.date.available2018-09-14T11:15:09Z
dc.date.issued2015-02-01en_US
dc.description.abstractDengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
dc.identifier.urihttps://demo7.dspace.org/handle/10673/219
dc.languageEnglishen_US
dc.titleA new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virusen_US
dc.typeJournal Article
dspace.entity.typePublication
relation.isAuthorOfPublicationb1b2c768-bda1-448a-a073-fc541e8b24d9
relation.isAuthorOfPublication.latestForDiscoveryb1b2c768-bda1-448a-a073-fc541e8b24d9
Files
Collections